|1.||Dionisio, Paolo: 3 articles (01/2009 - 01/2005)|
|2.||Kurosawa, Tohru: 2 articles (06/2009 - 02/2004)|
|3.||Ruggieri, Alessandro: 2 articles (01/2009 - 01/2007)|
|4.||Picollo, Rossella: 2 articles (01/2009 - 01/2007)|
|5.||Barattè, Simona: 2 articles (01/2009 - 01/2007)|
|6.||Crisanti, Anna: 1 article (12/2015)|
|7.||Bellussi, Luisa Maria: 1 article (12/2015)|
|8.||Passali, Desiderio: 1 article (12/2015)|
|9.||Nandi, Utpal: 1 article (09/2012)|
|10.||Pal, Tapan Kumar: 1 article (09/2012)|
12/01/1996 - "In conclusion, prulifloxacin (NM394) showed potent antibacterial activity against clinical isolates and potent therapeutic efficacy against experimental infection in spite of its lower AUCs compared with the reference drugs. "
01/01/2006 - "In conclusion, the in vitro inhibitory and bactericidal activities exhibited by ulifloxacin and the favorable characteristics shown by its prodrug (prulifloxacin) in clinical trials, particularly indicate this drug for the treatment of lung and urinary infections."
01/01/2009 - "These findings confirm the ability of prulifloxacin to penetrate prostatic tissues, indicating high exposure of the target tissue to ulifloxacin and, therefore, a potential therapeutic role for prulifloxacin in the treatment of bacterial prostatic infections."
|2.||Bacterial Infections (Bacterial Infection)
01/01/2007 - "Tissue concentrations observed after repeated administrations were generally higher than the ulifloxacin minimum inhibitory concentrations for pathogens more frequently involved in gynaecological bacterial infections. "
03/01/1996 - "These results suggest that uptake of NM394 by human polymorphonuclear leukocytes occurs via an active transport system differing from that of ofloxacin, whose uptake is affected by the presence of L-glycine and L-leucine, and that once accumulated, NM394 remains intracellularly active and participates in protection against bacterial infection."
|4.||Cardiac Arrhythmias (Arrythmia)
12/01/2015 - "Ulifloxacin T1/2 and plasma and tissue concentrations including the nose-paranasal sinuses mucosa allow once daily administration at the dosage of 600 mg. Prulifloxacin shows a high safety profile: it is the fluoroquinolone with the lowest risk of cardiac arrhythmias for prolongation of the QT interval; the CNS penetration is negligible; in women prulifloxacin does not affect the lactobacillary component of the vaginal microbiota, lowering the risk of genito-urinary tract infections. "
02/01/2004 - "In this in vivo study using a rabbit arrhythmia model, we assessed the proarrhythmic effects and changes in the QT interval elicited by the administration of NM394 (UFX), an active metabolite of the new quinolone antibiotic prulifloxacin, and three representative quinolones, sparfloxacin (SPFX), gatifloxacin (GFLX) and levofloxacin (LVFX). "
03/01/2009 - "Ulifloxacin and other oral comparator agents were tested for activity against 582 gastroenteritis strains from global surveillance studies. "
03/01/2009 - "Presently approved for clinical use in certain European countries and Japan, ulifloxacin was the most active of the antimicrobial agents tested against these gastroenteritis-causing pathogens."
|4.||Glycine (Aminoacetic Acid)
|10.||sparfloxacin (AT 4140)